Navigation Links
InspireMD Files At-the-Market Offering and Shelf Registration Statement
Date:10/24/2013

the U.S. by the FDA at this time.

Forward-looking Statements:

This press release contains "forward-looking statements." Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market acceptance of our existing and new products, (ii) negative clinical trial results or lengthy product delays in key markets, (iii) an inability to secure regulatory approvals for the sale of our products, (iv) intense competition in the medical device industry from much larger, multinational companies, (v) product liability claims, (vi) our limited manufacturing capabilities and reliance on subcontractors for assistance, (vii) insufficient or inadequate reimbursement by governmental and other third party payers for our products, (viii) our efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be successful, (ix) legislative or regulatory reform of the healthcare system in both the U.S. and foreign jurisdictions, (x) our reliance on single suppliers for certain product components, (xi) the fact that we will need to raise additional capital to meet our business requirements in the future and that such capital raising may be costly, dilutive or difficult to obtain and (xii) the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations,
'/>"/>

SOURCE InspireMD
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. InspireMD Elects Sol J. Barer, Ph.D. Chairman of the Board of Directors
2. InspireMD Appoints Dr. James Barry to Its Board of Directors
3. InspireMD to Present at JMP Securities Healthcare Conferenceon July 12th in New York
4. InspireMD to Present at JMP Securities Healthcare Conference on July 12th in New York
5. InspireMD Reports 2012 Fiscal Year Results
6. InspireMD Postpones $40 Million Registered
7. Michael Berman Joins InspireMD Board
8. InspireMD Hires Vice President of Corporate Development
9. InspireMD To Participate In Benchmark Investor Conference On May 30th
10. InspireMD Secures Financing to Accelerate Advancements in Product Development and Adopts a One Year Stockholder Rights Plan
11. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... 14, 2014 As pet owners drew up their lists of ... wrote: "Take better care of my furry companion." Nowadays there are ... top-brand carrying cases to take the little canine or feline darlings ... compelled to buy some pricey toys at the pet store. But ...
(Date:1/14/2014)... Jan. 14, 2014 The largest international professional ... plants and therapeutic derivatives thereof has endorsed an ... researchers about the challenges of adulterated herb and ... The Society for Medicinal Plant ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 iLab Solutions, the ... as the new Director of Product Strategy. In this role, ... as iLab sub-teams to guide in the development of iLab ... provides the maximum possible benefit to the scientific community by ...
(Date:1/14/2014)... , Jan. 14, 2014  RXi Pharmaceuticals Corporation ... developing and commercializing innovative therapies addressing major unmet ... it received the Notice of Allowance from the ... unique self-delivering RNAi compounds (sd-rxRNA®), for the treatment ...
Breaking Biology Technology:New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 4World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 5World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 6World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 7World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 8iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3
... call and webcast to begin after markets close at 2:00 p.m. PT ... ... Masimo Corporation,(Nasdaq: MASI ), the inventor of Pulse CO-Oximetry and,Measure-Through-Motion- ... the period ended,September 27, 2008 after the market closes on Monday, October ...
... Oct. 15 PURE Bioscience (Nasdaq:,PURE), creators of ... revenues for the fiscal year ended July 31, ... with $336,400 in the,prior fiscal year. The Company ... or $(0.24) per share, compared with a loss ...
... Agency Expanding Industry Connections, MOUNTAINSIDE, N.J., Oct. ... medical education company,today announced the hiring of Todd ... leverage his experience in medical education and,publishing as ... L&M, he,served as Manager of Publication Sales at ...
Cached Biology Technology:Masimo to Report Third Quarter 2008 Financial Results on October 27, 2008 2PURE Bioscience Reports Fourth Quarter and Year End Results 2PURE Bioscience Reports Fourth Quarter and Year End Results 3PURE Bioscience Reports Fourth Quarter and Year End Results 4PURE Bioscience Reports Fourth Quarter and Year End Results 5PURE Bioscience Reports Fourth Quarter and Year End Results 6PURE Bioscience Reports Fourth Quarter and Year End Results 7L&M Healthcare Communications LLC Expands Client Services With Executive Team Expansion 2
(Date:7/9/2014)... Bacterial infections usually announce themselves with pain and fever but ... are those that are sneaky and hard to beat. Now, ... the form of tiny DNA pyramids. Published in the journal ... the nanopyramids can flag bacteria and kill more of them ... note that some infectious pathogens can lie in wait, undetectable ...
(Date:7/9/2014)... by researchers at the NIH,s National Center ... collaborators to treat sickle cell disease has ... The drug candidate, Aes-103, is the first ... mechanism of sickle cell disease. Baxter now ... for regulatory approval and commercialization. , Sickle ...
(Date:7/9/2014)... vitamin D in their blood are more likely to survive ... highest levels of vitamin D have half the risk of ... reveal. , The study is the first to correlate total ... their diagnosis which includes that produced after exposure to ... long term survival prospects. , The University of Edinburgh ...
Breaking Biology News(10 mins):First drug candidate from NIH program acquired by biopharmaceutical company 2First drug candidate from NIH program acquired by biopharmaceutical company 3First drug candidate from NIH program acquired by biopharmaceutical company 4
... Foundation announced that five scientists with novel approaches to ... Damon Runyon-Rachleff Innovation Award. The grant of $450,000 ... career scientists whose projects have the potential to significantly ... The 2011 Damon Runyon-Rachleff Innovators are: ...
... Frontotemporal dementia is caused by a breakdown of nerve ... brain (fronto-temporal lobe), which leads to, among other symptoms, ... some forms of frontotemporal dementia is a genetically determined ... Dr. Anja Capell and Prof. Christian Haass have now ...
... Invasive plant species are a serious environmental, economic and ... native biodiversity and ecosystem functions, such as nutrient cycling. ... why some species dominate new habitats over native plants ... but rarely tested assumption, say biologists, is that these ...
Cached Biology News:Damon Runyon-Rachleff Innovation Awards granted for pioneering ideas in cancer research 2Damon Runyon-Rachleff Innovation Awards granted for pioneering ideas in cancer research 3Malaria medication may help against 1 type of frontotemporal dementia 2Home and away: Are invasive plant species really that special? 2
Rabbit polyclonal to Staphylococcus Enterotoxin E (Biotin) ( Abpromise for all tested applications)....
Rabbit polyclonal to Peptide E ( Abpromise for all tested applications)....
... siSolutions siRNA Custom Synthesis ... effective duplex RNA to knockdown ... 21-mers (19 RNA base pairs ... recently-published 27-mers, or other lengths ...
... first fully genetically encoded fluorescent sensor capable ... peroxide (H2O2), one of the main ROS ... of yellow fluorescent protein inserted into the ... (OxyR-RD), HyPer demonstrates submicromolar affinity to H2O2 ...
Biology Products: